Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pall signs Japanese deal for blood screen technology:

This article was originally published in Clinica

Executive Summary

Kawasumi Laboratories of Tokyo is to distribute Pall's eBDS (enhanced Bacterial Detection System) in Japan. Under the exclusive deal, Kawasumi will also be responsible for obtaining Japanese regulatory approval for the technology, which received US FDA clearance in January 2004. eBDS can detect bacteria in platelets derived both from single donors and random donor collection and automatically provide pass/fail results in 30 seconds. Bacteria contaminate between one in 2,000 and one in 5,000 platelets collected worldwide, says Pall. There are about 780,000 platelet collections in Japan every year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel